
    
      The purpose of the study is to determine the safety and efficacy of two dosing regimens of
      daclizumab as an adjunctive immunosuppressive agent in simultaneous kidney/pancreas
      transplant recipients receiving tacrolimus, mycophenolate mofetil, and steroids as primary
      maintenance immunosuppression.
    
  